Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A New Recombinant Bacille Calmette‐Guérin Vaccine Safely Induces Significantly Enhanced Tuberculosis‐Specific Immunity in Human Volunteers

22 Sept 2008

Abstract excerpt

BACKGROUND: One strategy for improving anti-tuberculosis (TB) vaccination involves the use of recombinant bacille Calmette-Guérin (rBCG) overexpressing protective TB antigens. rBCG30, which overexpresses the Mycobacterium tuberculosis secreted antigen Ag85b, was the first rBCG shown to induce significantly greater protection against TB in animals than parental BCG. METHODS: We report here the first double-blind...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immune responses and vaccinations
Share to Immunodeficiency and Autoimmune Disorders
Share to Tuberculosis Research and Epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18808333
DOI: 10.1086/592450

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A New Recombinant Bacille Calmette‐Guérin Vaccine Safely Induces Significantly Enhanced Tuberculosis‐Specific Immunity in Human VolunteersPMID 18808333Read ↗

Recombinant BCG: innovations on an old vaccine. Scope of BCG strains and strategies to improve long-lasting memorySemantic proximity Read ↗

Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 TrialSemantic proximity Read ↗

BCG as a Case Study for Precision Vaccine Development: Lessons From Vaccine Heterogeneity, Trained Immunity, and Immune OntogenySemantic proximity Read ↗

New live attenuated tuberculosis vaccine MTBVAC induces trained immunity and confers protection against experimental lethal pneumoniaSemantic proximity Read ↗

MTBVAC: Attenuating the Human Pathogen of Tuberculosis (TB) Toward a Promising Vaccine against the TB EpidemicSemantic proximity Read ↗

A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-GuérinSemantic proximity Read ↗

Genetic Modification of the BCG Vaccine to Overcome Its Limited Efficacy in Adults: A Specialized ReviewSemantic proximity Read ↗

Improving vaccines against tuberculosisSemantic proximity Read ↗

New Advances in the Development and Design of Mycobacterium tuberculosis Vaccines: Construction and Validation of Multi-Epitope Vaccines for Tuberculosis PreventionSemantic proximity Read ↗

Mycobacterial EsxG·EsxH (TB9.8·TB10.4) peptides as a subunit vaccine to booster BCG vaccination in an experimental model of pulmonary TuberculosisSemantic proximity Read ↗

DNA and RNA vaccines against tuberculosis: a scoping review of human and animal studiesSemantic proximity Read ↗

TB vaccines: current status and future perspectivesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.